Contamination risk sparks recall of GSK, Scynexis antifungal drug

The latest stories trending on MedCity News.

Editor's Pick

Top Story Contamination Risk Sparks a Recall of GSK, Scynexis Antifungal Drug Scynexis said no adverse events or contamination problems have been reported for Brexafemme, an antifungal approved for treating vaginal yeast infections. The biotech said the risk of cross-contamination stems from the processes of the small molecule's third-party manufacturer. Sponsored Content US Prescription Drug Costs More Than Double Those in Canada Presented by NexToronto and MedCity News Increasingly, patients in the U.S. look to Canada for more affordable prescription options since the Canadian government regulates drug costs. Some companies have noticed and are beginning to capitalize on the demand. Read More. Please Tell Us What You Think If you haven't already - You still have time to provide us feedback on what works for you and what doesn't on MedCity News. Please take a few moments to share your thoughts. At the end of the survey, you can enter to win a $250 gift card. Thank you. Take Survey Now

Featured News

Digital Therapeutics: A Panacea for Care or Overvalued Health Tech? Digital therapeutics will be one of the topics discussed at INVEST Digital Health scheduled for October 26 at Health Wildcatters headquarters in Pegasus Park in Dallas. Register today! Study: MA Beneficiaries Have Lower Utilization Than Traditional Medicare A new study found that MA beneficiaries have more than 50% fewer inpatient stays and 22% fewer emergency department visits than traditional Medicare enrollees. Novo Nordisk Turns to Flagship's Valo Health for AI-Driven Cardio Drug R&D Novo Nordisk is paying Valo Health $60 million up front to gain three preclinical cardiovascular disease programs. Milestone payments for those programs and others covered under the artificial intelligence drug discovery pact could reach up to $2.7 billion. Nursing Homes, Beware! Supreme Court Greenlights Civil Lawsuits to Enforce FNHRA The Supreme Court's recent summer decision in Health and Hospital Corporation of Marion County, Indiana, et al. v. Talevski has raised the stakes for nursing homes by ruling that private litigants may bring civil claims against facilities to recover damages for violations of certain provisions of the Federal Nursing Home Reform Act (FNHRA). This decision provides powerful incentives for nursing homes and other facilities subject to the FNHRA to enhance their monitoring and compliance processes. The 3 Areas that Concern Business Group on Health's CEO Issues around healthcare affordability, mental health challenges and worsening chronic conditions are all top of mind for Ellen Kelsay, president and CEO of Business Group on Health.

Resources

Introducing MedCity FemFwd, a New Podcast on Women's Health In the inaugural episode of the MedCity FemFwd podcast, Michelle Long, senior policy analyst for the Women's Health Policy program at KFF, talks about Opill, which recently made headlines as the first daily oral contraceptive approved for nonprescription use in the U.S. Long tells listeners why this news is significant and examines whether the medication will be covered by insurance. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe